Merck KGaA (MKGAF)
(Delayed Data from OTC)
$162.23 USD
+0.23 (0.14%)
Updated May 3, 2024 03:28 PM ET
4-Sell of 5 4
A Value D Growth C Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
MKGAF 162.23 +0.23(0.14%)
Will MKGAF be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for MKGAF based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MKGAF
HEXO (HEXO) Reports Q3 Loss, Lags Revenue Estimates
Catalent (CTLT) Reports Q3 Loss, Tops Revenue Estimates
MKGAF: What are Zacks experts saying now?
Zacks Private Portfolio Services
Journey Medical Corporation (DERM) Reports Q1 Loss, Lags Revenue Estimates
Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates
Relay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Misses Revenue Estimates
Other News for MKGAF
908 Devices: Rare Early-Stage Bioprocess Investment Opportunity
Week In Review: 3 Multinationals Plan Investments In Southeast Asia Facilities
Merck KGaA: Moving To A Hold As 2025 Targets Are Now Doubtful
Merck KGaA (MKGAF) Q4 2023 Earnings Call Transcript
Merck KGaA Non-GAAP EPS of €8.49, revenue of €20.99B; initiates FY24 outlook